MaxCyte
MaxCyte is a leader in cell transfection, bringing to market its patented flow electroporation technology. MaxCyte is focused in applying its significant capabilities in the discovery, development, and manufacturing of virtually all classes of innovative therapeutics targeting a broad range of chronic and acute diseases. MaxCyte’s customers and partners utilize its technologies in the development and commercialization of cell-based therapies in regenerative medicineand active cell immunotherapies and in the discovery and development of protein drugs, monoclonal antibodies, vaccines, and small molecule drugs. This clinical-grade cell loading technology is fully developed and well validated and has received Master File designation with the CBER Division of the U.S. FDA, has been cleared by NIH’s RAC and Health Canada, and is commercialized in Japan. Considerable energy is devoted to R&D on new applications. These efforts have lead to the expanded application of our technology in pharmaceutical and biotherapeutic drug discovery pipelines. Our instrumentation is currently placed in most of the major global pharmaceutical companies and is used for high throughput/high content screening and preclinical protein production. MaxCyte’s technology uniquely fulfills the needs for high quality, fully scalable cell modification in both the clinical and R&D arenas.
MaxCyte’s technology is protected by U.S. patents issued and allowed, with over 40 U.S. and international pending patents.
MaxCyte’s History
MaxCyte was founded in 1999 to commercialize flow electroporation technology from the CBR Institute for Biomedical Research in Boston, Massachusetts. This technology was initially intended for the treatment of ischemic disorders with theinitial clinical application of using flow electroporation to load 1 liter of an autologous red blood cell suspension with an alternative hemoglobin oxygen modulator. MaxCyte pursued the red blood cell application as well as investigated the use of the technology for loading a wide range of biologically active molecules into a variety of cell types.
Our scientist have significantly refined flow electroporation and explored many new clinical and commercial applications. Most recently, drawing on its cell therapy expertise, MaxCyte designed the MaxCyte® STX™ Scalable Transfection System for the rapid, scalable and reagent-free (co)transfection of primary cells, stem cells, and cell lines involved in the burgeoning areas of cell-based assays for high throughput and high content screening, preclinical protein production, and small molecule drug discovery.
MaxCyte’s Facilities and Resources
MaxCyte occupies a modern facility in Gaithersburg, Maryland, with more than 50% of the facility dedicated to research and development. We have a well-equipped cell and molecular biology laboratory as well as dedicated tissue culture rooms, including bioreactor systems, cell separation, and analysis systems. MaxCyte engineers design, develop, assemble, and manufacture the electroporation instrumentation and cell processing chambers on-site. This ensures timely delivery of precision-quality products to our clients. The Company’s scientific team has unparalleled expertise and continues to make significant advances in developing the flexibility and cutting-edge clinical and commercial applications of flow electroporation.
